Evidence map›Paper›PMID 33921615›Full record

ReviewInternational journal of molecular sciences2021

Could Lipoxins Represent a New Standard in Ischemic Stroke Treatment?

Nikola Tułowiecka, Dariusz Kotlęga, Andrzej Bohatyrewicz, Małgorzata Szczuko

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Molecular Mechanisms of Cerebrovascular Diseases.International journal of molecular sciences · 2022
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nikola TułowieckaDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, Broniewskiego 24 Street, 71-460 Szczecin, Poland.
Dariusz KotlęgaDepartment of Neurology, District Hospital, 67-200 Głogów, Poland.ORCID 0000-0002-3116-9656
Andrzej BohatyrewiczDepartment of Orthopaedics, Pomeranian Medical University, Żołnierska 48, 71-210 Szczecin, Poland.
Małgorzata SzczukoDepartment of Human Nutrition and Metabolomics, Pomeranian Medical University, Broniewskiego 24 Street, 71-460 Szczecin, Poland.ORCID 0000-0001-9808-0624
Pomeranian Medical University · PLState Higher Vocational School in Głogów · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCardiovascular diseases including stroke are one of the most common causes of death. Their main cause is atherosclerosis and chronic inflammation in the body. An ischemic stroke may occur as a result of the rupture of unstable atherosclerotic plaque. Cardiovascular diseases are associated with uncontrolled inflammation. The inflammatory reaction produces chemical mediators that stimulate the resolution of inflammation. One of these mediators is lipoxins-pro-resolving mediators that are derived from the omega-6 fatty acid family, promoting inflammation relief and supporting tissue regeneration.

aimThe aim of the study was to review the available literature on the therapeutic potential of lipoxins in the context of ischemic stroke. MATERIAL AND

methodsArticles published up to 31 January 2021 were included in the review. The literature was searched on the basis of PubMed and Embase in terms of the entries: 'stroke and lipoxin' and 'stroke and atherosclerosis', resulting in over 110 articles in total. Studies that were not in full-text English, letters to the editor, and conference abstracts were excluded.

resultsIn animal studies, the injection/administration of lipoxin A4 improved the integrity of the blood-brain barrier (BBB), decreased the volume of damage caused by ischemic stroke, and decreased brain edema. In addition, lipoxin A4 inhibited the infiltration of neutrophils and the production of cytokines and pro-inflammatory chemokines, such as interleukin (Il-1β, Il-6, Il-8) and tumor necrosis factor-α (TNF-α). The beneficial effects were also observed after introducing the administration of lipoxin A4 analog-BML-111. BML-111 significantly reduces the size of a stroke and protects the cerebral cortex, possibly by reducing the permeability of the blood-brain barrier. Moreover, more potent than lipoxin A4, it has an anti-inflammatory effect by inhibiting the production of pro-inflammatory cytokines and increasing the amount of anti-inflammatory cytokines.

conclusionsLipoxins and their analogues may find application in reducing damage caused by stroke and improving the prognosis of patients after ischemic stroke.

Indexed as

AnimalsBrain IschemiaFatty Acids, Omega-6HumansIschemic StrokeLipoxinsStrokeFatty Acids, Omega-6Lipoxinsarachidonic acidcardiovascular diseaseinflammationischemic strokelipoxins

Identifiers

PMID33921615
PMCPMC8074032
OpenAlexW3153394009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.